Sample results
Beckwith-Wiedemann syndrome is a rare congenital overgrowth disorder characterized by excessive growth, enlarged organs, and increased cancer risk. It is caused by genetic and epigenetic changes affecting chromosome 11p15.5, leading to overexpression of the IGF-2 gene. The IGF-2 blood test is the most important test for monitoring this syndrome because it measures the growth factor levels that drive overgrowth and tumor development.
Beckwith-Wiedemann syndrome is caused by genetic and epigenetic alterations on chromosome 11p15.5 that disrupt normal growth regulation. These changes lead to overexpression of the IGF-2 gene and reduced expression of growth-suppressing genes like CDKN1C. The result is uncontrolled cell growth during fetal development and early childhood. Most cases occur sporadically without family history, though about 10-15% are inherited in an autosomal dominant pattern with parent-of-origin effects, meaning the genetic change matters depending on whether it comes from the mother or father.
The IGF-2 blood test is the most important laboratory test for Beckwith-Wiedemann syndrome because it measures insulin-like growth factor-2 levels, which are typically elevated due to IGF-2 gene overexpression. This test helps monitor the biochemical activity driving excessive growth and increased tumor risk in affected individuals. While genetic testing through methylation analysis and chromosomal studies confirms the diagnosis, the IGF-2 test provides valuable ongoing monitoring information. Healthcare providers use IGF-2 levels alongside regular ultrasound screening and alpha-fetoprotein testing to assess tumor development risk and guide clinical management decisions throughout childhood.
You should get tested if your child shows signs of excessive growth, such as being significantly larger than expected for their age, having one side of the body larger than the other, or displaying an enlarged tongue that protrudes from the mouth. Testing is also important if your baby is born with abdominal wall defects, creases in the earlobes, or experiences repeated episodes of low blood sugar in infancy. Early testing allows for prompt tumor surveillance and management of complications, which significantly improves long-term outcomes for children with this condition.
What this means
Your IGF-2 levels are slightly below the optimal range. While this alone isn't definitive, it may contribute to slower growth patterns or reduced cellular growth signals, especially when considered alongside other growth markers like IGF-1.
Recommended actions
Ensure adequate protein intake from quality sources like lean meats, fish, eggs, and dairy
Prioritize 8-10 hours of quality sleep per night, as growth factors are released during deep sleep
Work with your healthcare provider to evaluate IGF-1 and growth hormone levels for a complete assessment
Consider retesting in 3-6 months to monitor trends and treatment response
Not overhyped or overpriced. Just comprehensive blood testing made simple and for everyone.
Sample results
Your 24/7 Personal Lab Guide
Quick questions: